Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
12 Aug 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
8 Aug 24
8-K
Amendments to Articles of Incorporation or Bylaws
10 Jun 24
8-K
Entry into a Material Definitive Agreement
10 May 24
S-3ASR
Automatic shelf registration
10 May 24
S-8
Registration of securities for employees
9 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
9 May 24
DEFA14A
Additional proxy soliciting materials
7 May 24
8-K
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors
7 May 24
DEFA14A
Additional proxy soliciting materials
26 Apr 24
DEF 14A
Definitive proxy
26 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
22 Feb 24
424B5
Prospectus supplement for primary offering
19 Jan 24
8-K
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock
19 Jan 24
8-K
Results of Operations and Financial Condition
19 Jan 24
S-3MEF
Registration of additional securities for an S-3
19 Jan 24
424B3
Prospectus supplement
19 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Results of Operations and Financial Condition
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Results of Operations and Financial Condition
10 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
14 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Jun 23
8-K
Entry into a Material Definitive Agreement
16 Jun 23
424B5
Prospectus supplement for primary offering
16 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
12 Jun 23
S-8
Registration of securities for employees
11 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Results of Operations and Financial Condition
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors
6 Mar 23
10-K
2022 FY
Annual report
23 Feb 23
8-K
Results of Operations and Financial Condition
23 Feb 23
8-K
Results of Operations and Financial Condition
3 Nov 22
Latest ownership filings
4
Alan J Russell
24 Sep 24
4
JOHN R MOORE
24 Sep 24
4
Joanne M. Donovan
24 Sep 24
4
Behrad Derakhshan
24 Sep 24
4
R Michael Carruthers
24 Sep 24
SC 13D/A
Novo Holdings A/S
23 Sep 24
144
Notice of proposed sale of securities
23 Sep 24
144
Notice of proposed sale of securities
20 Sep 24
144
Notice of proposed sale of securities
20 Sep 24
144
Notice of proposed sale of securities
20 Sep 24
144
Notice of proposed sale of securities
20 Sep 24
144
Notice of proposed sale of securities
20 Sep 24
4
Marc Semigran
14 Aug 24
4
Alan J Russell
14 Aug 24
4
JOHN R MOORE
14 Aug 24
4
Behrad Derakhshan
14 Aug 24
4
KEVIN KOCH
14 Aug 24
4
Joanne M. Donovan
14 Aug 24
4
R Michael Carruthers
14 Aug 24
SC 13G/A
FMR LLC
10 Jul 24
4
Peter A. Thompson
12 Jun 24
4
Jonathan C Fox
12 Jun 24
4
Arlene Morris
12 Jun 24
4
Laura Brege
12 Jun 24
4
Badreddin Edris
12 Jun 24
4
JONATHAN D ROOT
12 Jun 24
4
Arlene Morris
7 May 24
3
Arlene Morris
7 May 24
4
JOHN R MOORE
3 May 24
4
R Michael Carruthers
3 May 24
4
Behrad Derakhshan
3 May 24
4
Alan J Russell
3 May 24
4
Joanne M. Donovan
3 May 24
4
KEVIN KOCH
3 May 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
4
JOHN R MOORE
9 Feb 24
4
Behrad Derakhshan
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
BlackRock Inc.
7 Feb 24